Differences in serum GH cut-off values for pharmacological tests of GH secretion depend on the serum GH method. Clinical validation from the growth velocity score during the first year of treatment.
BACKGROUND
The serum GH cut-off value for pharmacological tests of GH secretion (PhT GH) depends on the type of test and also on the method used for determining serum GH. Cut-off serum GH values as different as 5-10 ng/ml, have been reported, and have been validated biochemically. We have used the growth velocity (GV)-standard deviation score (SDS) during the first year of treatment with rhGH to validate these cut-offs on a biological basis.


METHODS
Fifty pre-pubertal patients with short stature (height < or =-2 SDS and GV < or =-1.2 SDS) were studied. GH deficiency (GHD) was diagnosed in 39 patients, on the basis of clinical and auxological parameters and on the serum concentration of IGF-1, and non-GHD in the other 11 patients. Two PhT GH (arginine and clonidine) were carried out in the 50 patients. Serum GH was determined by two different methods: one detecting most of serum GH isoforms, named Total GH (HGH Bio-Tech, MAIA Clone), and another one, only detecting the 22 kDa GH, named 22K GH (GH-22K IFMA, Wallac).


RESULTS
Basal data: all patients with GHD and with non-GHD had maximal serum GH response (MaxR) values below and above the cut-off, respectively, for the serum Total GH and 22K GH. The mean 22K GH/Total GH ratio was similar to previous publications. Post-rhGH treatment data: the two groups improved their height SDS during the first year of treatment, particularly patients with GHD. A receiver-operator curve was used to define the best threshold for post-treatment GV-SDS that separates GHD from non-GHD patients. This value was 1.91 GV-SDS. A negative correlation between first year treatment GV-SDS and pre-treatment serum GH MaxR was found for the two assays (p < 0.001). Then, the best cut-off GV-SDS, previously calculated with the receiver-operator curve (1.91 SDS) was used to interpolate the corresponding serum GH values, as determined by the two methods. For Total GH, the value was 10.8 ng/ml, and for 22K GH, it was 5.4 ng/ml.


CONCLUSIONS
The cut-off values calculated by biological means to separate GHD from non-GHD were remarkably similar to those calculated biochemically (10.0 and 4.8 ng/ml, respectively) for Total and 22K GH. This is a biological validation for using different cut-off values, appropriate for each assay, to diagnose GHD.
Chaler
E A
EA
Servicio de Endocrinologia, Hospital de Pediatria Garrahan, Buenos Aires, Argentina. echaler@yahoo.com
Rivarola
M A
MA
Guerci
B
B
Ciaccio
M
M
Costanzo
M
M
Travaglino
P
P
Maceiras
M
M
Pagani
S
S
Meazza
C
C
Bozzola
E
E
Barberi
S
S
Bozzola
M
M
Belgorosky
A
A
D000293:Adolescent; D001681:Biological Assay / Q000379:methods; D001827:Body Height / Q000187:drug effects; D002648:Child; D004393:Dwarfism, Pituitary / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006130:Growth Disorders / Q000097:blood* / Q000188:drug therapy; D019382:Human Growth Hormone / Q000097:blood* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010446:Peptide Fragments / Q000097:blood* / Q000627:therapeutic use; D012680:Sensitivity and Specificity
D010446:Peptide Fragments; C404802:human growth hormone 22K; D019382:Human Growth Hormone